Takeda Pharmaceutical Co (FRA:TKD) FFO


FRA:TKD Takeda Pharmaceutical Co Ltd FRA:TKD
68 GF Score
Price €27.73
GF Value €24.70
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

FRA:TKD
68GF Score
Takeda Pharmaceutical Co Ltd FRA:TKD
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Takeda Pharmaceutical Co (FRA:TKD) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of €27.73 is trading 12.3% above its estimated GF Value™ of €24.70. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:TKD:

  • FFO:
  • GF Value™: €24.70 vs. price of €27.73 (12.3% above fair value)
  • GF Score™: 68/100 with 6 warning signs

No single metric tells the full story. See the FRA:TKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
68GF Score

Get the complete analysis for FRA:TKD

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.73
Price
€24.70
GF Value